M
MoonLake Immunotherapeutics
Biotech & Life Sciences · Zug, Switzerland · Founded 2021 · Public via SPAC 2022
MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including… MoreLess
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious inflammatory diseases. The company operates in the healthcare sector, specifically targeting conditions with significant unmet medical needs such as hidradenitis suppurativa and psoriatic arthritis. MoonLake's primary asset is Sonelokimab, a novel therapeutic agent currently undergoing Phase 2 clinical trials. The business model revolves around advancing Sonelokimab through clinical development stages, securing regulatory approvals, and eventually commercializing the drug. Revenue generation is anticipated through partnerships, licensing agreements, and direct sales upon successful market entry. MoonLake serves patients, healthcare providers, and the broader medical community by offering potential new treatment options that aim to improve patient outcomes and quality of life. Key partnerships, such as the development and manufacturing agreement with Vetter Pharma International GmbH, bolster their operational capabilities. The company has also been recognized for its achievements, including winning the European Lifestars Awards for its successful business combination and fundraising efforts.
Keywords: biopharmaceutical, inflammatory diseases, Sonelokimab, Phase 2 trials, hidradenitis suppurativa, psoriatic arthritis, clinical-stage, healthcare, innovation, partnerships.
Company overview
MoonLake Immunotherapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Zug, Switzerland
- Employees
- 134
- Open positions
- 8
- Dealroom signal
- 85.4
Valuation & funding
MoonLake Immunotherapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $200M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Feb 2026 | $28M | — | Cormorant Asset Management | ↗ |
| POST IPO EQUITYOther financing | Nov 2025 | $75M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Apr 2025 | $75M | — | Hercules Capital | ↗ |
| POST IPO EQUITYOther financing | Jun 2023 | $400M | — | Undisclosed | ↗ |
| SPAC PRIVATE PLACEMENTOther financing | Apr 2022 | Tekla Capital Management · BVF Partners · Cormorant Asset Management · RTW Investments | — | ||
| SPAC IPOOther financing | Apr 2022 | Helix Acquisition Corp | — | ||
| SERIES AOther financing | May 2021 | EMD Performance Materials · Merck KGaA · BVF Partners | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$336M | — |
| 2025 | $0 | — | −$220M | — |
| 2024 | $0 | — | −$142M | — |
| 2023 | $0 | — | −$54M | — |
| 2022 | $0 | — | −$65M | — |
Growth signals
MoonLake Immunotherapeutics website traffic
Latest recorded traffic for MoonLake Immunotherapeutics is 12K monthly website visits, up 55.8% over the last three months. MoonLake Immunotherapeutics's team declined 3.6% over the past year.
Hiring
Open positions at MoonLake Immunotherapeutics
Current openings linked to this company in Dealroom.
Comparisons
MoonLake Immunotherapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
MoonLake Immunotherapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where MoonLake Immunotherapeutics has talent and traffic
team presence
In the news
Latest news about MoonLake Immunotherapeutics
Recent press, funding announcements, and product moves mentioning MoonLake Immunotherapeutics — open to read from the original sources.
Market sentiment
What the market is saying about MoonLake Immunotherapeutics
An AI-synthesized read of the highest-engagement posts about MoonLake Immunotherapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MoonLake Immunotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.